Read later
  • 09 Sep 2020

Prisym ID appoints sales director for North America

Prisym ID has appointed Robert Bowdish as director of clinical trials sales for North America

Prisym ID, one of the leading providers of regulated content and label management technologies, has appointed Robert Bowdish as director of clinical trials sales for North America.

Bowdish has extensive healthcare industry sales experience. Having started out working as a pharmaceutical sales representative 26 years ago, he has been specializing in the regulatory and clinical software solutions and services market for the past decade.

He has joined Prisym ID from Parexel Informatics, where he was initially appointed senior director for solutions consulting and then became senior director for regulatory clinical solutions and global sales, where he led a team of sales directors working across diverse sectors. Prior to that, he worked as a senior account executive for Truven Health Analytics, which was acquired by IBM Watson Health. Other posts that Bowdish has held include regional sales director for Takeda Pharmaceuticals in North America, leading a commercial team of 10 district managers and 100 sales representatives.

‘Robert Bowdish is a fantastic addition to our team at Prisym ID,’ commented Warren Stacey, SVP of sales at Prisym ID. ‘He will take the lead driving clinical trials sales in the North American market, building on his relationships with pharma and CROs, demonstrating how our market-leading products can be integrated into a clinical trial supply chain to deliver a compliant labeling solution.’

ABOUT THE AUTHOR

The Labels & Labeling global editorial team covers every corner of the world from Europe and the Americas, to India, Asia, Southeast Asia and Australasia with all the latest news from the label and package printing market.

See author’s profile »